Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Sweiss

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bone Marrow Transplantation|April 5, 2011
Deferasirox increases BU blood concentrationsK Sweiss, P Patel, D Rondelli
Maryland State Medical Journal|March 1, 1982
Gastric plasmocytomaA Ulfohn, M Raju, K Sweiss, et al.
Bone Marrow Transplantation|October 13, 2009
Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSFS Nimmagadda, K Sweiss, N Mahmud, et al.
Bone Marrow Transplantation|December 7, 2010
Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4)P Patel, K Sweiss, S Nimmagadda, et al.
Bone Marrow Transplantation|March 16, 2010
The impact of novel influenza A (H1N1) after hematopoietic SCTP Patel, K Sweiss, S Shatavi, et al.
Bone Marrow Transplantation|May 17, 2016
Melphalan 200 mg/m<sup>2</sup> in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survivalK Sweiss, S Patel, K Culos, et al.
Bone Marrow Transplantation|October 6, 2015
Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplantA L Oh, P Patel, K Sweiss, et al.
Bone Marrow Transplantation|March 21, 2017
Non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide cures the first adult patient with congenital dyserythropoietic anemiaA Oh, P R Patel, N Aardsma, et al.
Bone Marrow Transplantation|June 23, 2009
Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimenR Beri, S Chunduri, K Sweiss, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bone Marrow Transplantation|April 5, 2011
Deferasirox increases BU blood concentrationsK Sweiss, P Patel, D Rondelli
Maryland State Medical Journal|March 1, 1982
Gastric plasmocytomaA Ulfohn, M Raju, K Sweiss, et al.
Bone Marrow Transplantation|October 13, 2009
Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSFS Nimmagadda, K Sweiss, N Mahmud, et al.
Bone Marrow Transplantation|December 7, 2010
Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4)P Patel, K Sweiss, S Nimmagadda, et al.
Bone Marrow Transplantation|March 16, 2010
The impact of novel influenza A (H1N1) after hematopoietic SCTP Patel, K Sweiss, S Shatavi, et al.
Bone Marrow Transplantation|May 17, 2016
Melphalan 200 mg/m<sup>2</sup> in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survivalK Sweiss, S Patel, K Culos, et al.
Bone Marrow Transplantation|October 6, 2015
Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplantA L Oh, P Patel, K Sweiss, et al.
Bone Marrow Transplantation|March 21, 2017
Non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide cures the first adult patient with congenital dyserythropoietic anemiaA Oh, P R Patel, N Aardsma, et al.
Bone Marrow Transplantation|June 23, 2009
Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimenR Beri, S Chunduri, K Sweiss, et al.
Pageof 1